FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287958183> ?p ?o ?g. }

• W4287958183 endingPage "44" @default.
• W4287958183 startingPage "35" @default.
• W4287958183 abstract "Men are three to four times more likely to be diagnosed with bladder cancer (BCa) than women, who often have more aggressive tumors. Intravesical bacillus Calmette-Guerin (BCG) for non–muscle-invasive bladder cancer (NMIBC) is one of the first immunotherapies, with use of immune checkpoint inhibitors for BCa immunotherapy expanding. Sex hormones, and notably androgens, might impact the outcome of these therapies. To understand immunological sex differences in BCa and investigate androgen receptor (AR) inhibition as a novel strategy to improve the response to BCa immunotherapy. Human NMIBC tumors were freshly collected following transurethral resection. In vivo studies used the subcutaneous MBT-2 BCa model in male and female C3H mice. The AR antagonist enzalutamide was given alone or in combination with anti–programmed cell death protein-1 (anti–PD-1) or intratumoral BCG + poly(I:C) treatments. Tumor growth and survival were evaluated in vivo. Flow cytometry and RNA sequencing characterized the immune cells present in murine and human tumors. Descriptive comparisons were performed for MBT-2 tumors between sexes and with human NMIBC tumors. The MBT-2 model shows multiple similarities to the immune composition of human NMIBC tumors and recapitulates previously observed human tumor immune cell sex differences. Enzalutamide in combination with either anti–PD-1 or BCG + poly(I:C) treatment in male mice synergized to improve response rates. Notably, the proportion of complete responses in male mice treated with the combination treatment resembles that observed in female mice with either immunotherapy alone. Limitations include the sample size for murine experiments. Our results suggest that combining AR antagonism with immunotherapy in male BCa patients may potentiate the antitumor immune response and increase response rates. The MBT-2 model appears relevant to investigate immunological BCa sex differences. Our studies suggest that combining antiandrogen treatments with BCa immunotherapy may improve response rates in men. We also demonstrate the utility of the MBT-2 mouse model to study sex differences in BCa." @default.
• W4287958183 created "2022-07-26" @default.
• W4287958183 creator A5005046774 @default.
• W4287958183 creator A5010847790 @default.
• W4287958183 creator A5046036722 @default.
• W4287958183 creator A5046141598 @default.
• W4287958183 creator A5065284552 @default.
• W4287958183 creator A5075327765 @default.
• W4287958183 creator A5076056554 @default.
• W4287958183 date "2022-09-01" @default.
• W4287958183 modified "2023-09-27" @default.
• W4287958183 title "Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment" @default.
• W4287958183 cites W1863833365 @default.
• W4287958183 cites W1989906144 @default.
• W4287958183 cites W2024400031 @default.
• W4287958183 cites W2142937869 @default.
• W4287958183 cites W2154017868 @default.
• W4287958183 cites W2162130153 @default.
• W4287958183 cites W2239178350 @default.
• W4287958183 cites W2463867199 @default.
• W4287958183 cites W2579440183 @default.
• W4287958183 cites W2602595893 @default.
• W4287958183 cites W2753239977 @default.
• W4287958183 cites W2783442236 @default.
• W4287958183 cites W2902691483 @default.
• W4287958183 cites W2905644126 @default.
• W4287958183 cites W2942610007 @default.
• W4287958183 cites W3006465944 @default.
• W4287958183 cites W3040217800 @default.
• W4287958183 cites W3061157080 @default.
• W4287958183 cites W3080561708 @default.
• W4287958183 cites W3093383535 @default.
• W4287958183 cites W3094308519 @default.
• W4287958183 cites W3096123211 @default.
• W4287958183 cites W3135161405 @default.
• W4287958183 cites W3167210801 @default.
• W4287958183 cites W3170421887 @default.
• W4287958183 cites W4206935838 @default.
• W4287958183 cites W4220826761 @default.
• W4287958183 doi "https://doi.org/10.1016/j.euros.2022.06.007" @default.
• W4287958183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36246841" @default.
• W4287958183 hasPublicationYear "2022" @default.
• W4287958183 type Work @default.
• W4287958183 citedByCount "7" @default.
• W4287958183 countsByYear W42879581832022 @default.
• W4287958183 countsByYear W42879581832023 @default.
• W4287958183 crossrefType "journal-article" @default.
• W4287958183 hasAuthorship W4287958183A5005046774 @default.
• W4287958183 hasAuthorship W4287958183A5010847790 @default.
• W4287958183 hasAuthorship W4287958183A5046036722 @default.
• W4287958183 hasAuthorship W4287958183A5046141598 @default.
• W4287958183 hasAuthorship W4287958183A5065284552 @default.
• W4287958183 hasAuthorship W4287958183A5075327765 @default.
• W4287958183 hasAuthorship W4287958183A5076056554 @default.
• W4287958183 hasBestOaLocation W42879581831 @default.
• W4287958183 hasConcept C121608353 @default.
• W4287958183 hasConcept C126322002 @default.
• W4287958183 hasConcept C143998085 @default.
• W4287958183 hasConcept C150903083 @default.
• W4287958183 hasConcept C203014093 @default.
• W4287958183 hasConcept C207001950 @default.
• W4287958183 hasConcept C2776551883 @default.
• W4287958183 hasConcept C2777701055 @default.
• W4287958183 hasConcept C2777742743 @default.
• W4287958183 hasConcept C2780057760 @default.
• W4287958183 hasConcept C2780192828 @default.
• W4287958183 hasConcept C2780352672 @default.
• W4287958183 hasConcept C2910016293 @default.
• W4287958183 hasConcept C502942594 @default.
• W4287958183 hasConcept C61367390 @default.
• W4287958183 hasConcept C71924100 @default.
• W4287958183 hasConcept C86803240 @default.
• W4287958183 hasConcept C8891405 @default.
• W4287958183 hasConceptScore W4287958183C121608353 @default.
• W4287958183 hasConceptScore W4287958183C126322002 @default.
• W4287958183 hasConceptScore W4287958183C143998085 @default.
• W4287958183 hasConceptScore W4287958183C150903083 @default.
• W4287958183 hasConceptScore W4287958183C203014093 @default.
• W4287958183 hasConceptScore W4287958183C207001950 @default.
• W4287958183 hasConceptScore W4287958183C2776551883 @default.
• W4287958183 hasConceptScore W4287958183C2777701055 @default.
• W4287958183 hasConceptScore W4287958183C2777742743 @default.
• W4287958183 hasConceptScore W4287958183C2780057760 @default.
• W4287958183 hasConceptScore W4287958183C2780192828 @default.
• W4287958183 hasConceptScore W4287958183C2780352672 @default.
• W4287958183 hasConceptScore W4287958183C2910016293 @default.
• W4287958183 hasConceptScore W4287958183C502942594 @default.
• W4287958183 hasConceptScore W4287958183C61367390 @default.
• W4287958183 hasConceptScore W4287958183C71924100 @default.
• W4287958183 hasConceptScore W4287958183C86803240 @default.
• W4287958183 hasConceptScore W4287958183C8891405 @default.
• W4287958183 hasLocation W42879581831 @default.
• W4287958183 hasLocation W42879581832 @default.
• W4287958183 hasLocation W42879581833 @default.
• W4287958183 hasLocation W42879581834 @default.
• W4287958183 hasOpenAccess W4287958183 @default.
• W4287958183 hasPrimaryLocation W42879581831 @default.
• W4287958183 hasRelatedWork W2177175549 @default.

• next